SPY759.50−0.04%QQQ689.19−0.17%BTC/USD74,420.91+0.98%DIA524.43−0.00%GLD365.13−0.01%TLT80.87−0.06%

Regeneron Pharmaceuticals Inc

REGNNASDAQ

$959.41

43.354.73%

Last update: Nov 11, 4:54 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Dividends Compare Options Stock Report

Dividend: The dividend Ex-Date is in 9 days

Regeneron Pharmaceuticals (REGN) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Regeneron Pharmaceuticals (REGN) stock.

Analyst Consensus — 24 Analysts

18Buy

5Hold

1Sell

# Analysts24

Latest Upgrades and Downgrades for Regeneron Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Leerink Partners	David Risinger	PT Raise	Market Perform	$835→$997
—	Bernstein	Jeffrey Walch	PT Raise	Market Perform	$756→$812
—	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$779→$855
—	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$810→$913
—	Truist Securities	Gregory Renza	PT Raise	Buy	$780→$982
—	Guggenheim	Yatin Suneja	PT Raise	Buy	$1030→$1100
—	Wells Fargo	Mohit Bansal	PT Raise	Equal-Weight	$750→$925
—	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$900→$1075
—	Canaccord Genuity	John Newman	PT Raise	Buy	$922→$1175
—	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$795→$980
—	Baird	Brian Skorney	PT Raise	Neutral	$761→$875
—	B of A Securities	Tazeen Ahmad	PT Raise	Buy	$908→$1030
—	JP Morgan	Chris Schott	PT Raise	Overweight	$950→$1050
—	Citigroup	Geoff Meacham	PT Raise	Neutral	$740→$825
—	Canaccord Genuity	John Newman	PT Raise	Buy	$875→$922
—	TD Cowen	Tyler Van Buren	PT Raise	Buy	$960→$980
—	Piper Sandler	Biren Amin	PT Raise	Overweight	$854→$865
—	UBS	Trung Huynh	Upgrade	Neutral→Buy	$660→$978
—	RBC Capital	Brian Abrahams	PT Raise	Sector Perform	$737→$810
—	Truist Securities	Gregory Renza	PT Raise	Buy	$772→$780

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals (REGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Regeneron Pharmaceuticals Stock

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals (REGN) Stock Price Target 2026

Latest Upgrades and Downgrades for Regeneron Pharmaceuticals Stock

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PROBernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PROCNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

People Also Watch

People Also Watch

Analyst Ratings News

PROLeerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PROBernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PROCNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PROMorgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRORBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PROTruist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982

PRO
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997

PRO
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812

PRO
CNBC Halftime Report Final Trades: Invesco S&P 500 Equal Weight Industrials Portfolio, Cleveland-Cliffs, UnitedHealth Group, Regeneron Pharmaceuticals

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913

PRO
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982